HUTCHMED
Manufacturing · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Kong Center 2 Queen's Rd Central Fl 48 C...Phone Number
+852 21281188Website
www.hutch-med.comRevenue
$630.2 MillionStock Symbol
HCMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About HUTCHMED
HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.Explore more
HUTCHMED Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HUTCHMED your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if HUTCHMED is spiking on competitors!
Check if HUTCHMED has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once HUTCHMED has new funding data
Product Launch: Get notified when HUTCHMED launches new products
Website visits: Recent activity has been detected on your website
HUTCHMED, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if HUTCHMED had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at HUTCHMED
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on HUTCHMED recently announced quarterly report
Recommended Actions
Find VP level buyers at HUTCHMED
Find more new buyers
Company Profile Activity
Activity Insights
HUTCHMED is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HUTCHMED is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HUTCHMED.
HUTCHMED financials insights
Gather financial insights about HUTCHMED, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$100M
Share Placement
$100M
2021
Share Placement
$100M
HUTCHMED Tech Stack
A closer look at the technologies used by HUTCHMED
Most Recent Scoops
Earnings
reported R&D expenses of $148 million for 2025. Expenses were lower versus 2024 as many late stage trials are in the completion stage, with multiple NDAs now awaiting approvals.
Earnings, Research & Development, Pharmaceuticals, Finance
Project
HUTCHMED has announced that TAZVERIK has been included in China's first commercial insurance drug list, where it is one of 19 medicines on the list. This provides future growth opportunities to explore commercial insurance.
Business Development, Pharmaceuticals
Project
HUTCHMED has announced that savolitinib has been approved in China for first and second-line MET exon 14 alteration as a single agent in non-small cell lung cancer.
Medical Research, Pharmaceuticals
Project
HUTCHMED has announced that savolitinib (SACHI) was approved in China in record speed for second-line EGFR mutant, MET-amplified non-small cell lung cancer.
Medical Research, Pharmaceuticals
Pain Point
Pain Point, Barriers
HUTCHMED News & Media
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration studyHUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products AdminisHUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California.HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma (“DLBCL”) in China. The first patient received the first dose on March 20, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HUTCHMED
Sign Up For FreeTo access detailed company insights
HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.... Read More
